Overview Efficacy and Dose Ranging Study of Seroguard Status: Completed Trial end date: 2018-01-23 Target enrollment: Participant gender: Summary This trial was a multi-center, double-blind, randomized, parallel group, placebo-controlled, phase II study in adult hospitalized female patients with the confirmed diagnosis of pelvic adhesive disease in Study centres in Russia. Phase: Phase 2 Details Lead Sponsor: PharmasyntezCollaborators: Cromos Pharma LLCCromos Pharma, LLC